Testosterone Replacement Therapy (TRT) or low testosterone therapy is
commonly called hormone therapy for men, designed to counteract the
effects of reduced activity in the gonads or hypogonadism.
Hypogonadism in men is clinical syndrome, which results in the
failure of the testes to produce physiological levels of
testosterone. Hypogonadism may be primary, due to a problem with the
testes or secondary due to a problem with the hypothalamus or
pituitary gland or combined: primary and secondary. Primary
hypogonadism is caused due to genetic abnormalities, testicular
trauma, orchitis, radiation treatment or chemotherapy, while
secondary hypogonadism is caused due to genetic abnormalities of
pituitary and hypothalamus.
Ask
for In-depth Sample Copy of This Research @
https://www.coherentmarketinsights.com/insight/request-sample/2024
Testosterone Replacement Therapy Market – Drivers
Hypogonadism in men is primarily characterized by reduced
concentration of serum testosterone, causing decreased libido,
erectile dysfunction, loss of body and facial hair, decreased bone
density, weakness, decreased lean body mass, increased body fat,
fatigue and anemia. Hypogonadism in adult men is often overlooked;
even in the presence of associated symptoms, because the hypogonadism
men often ignore the symptoms or they attribute them with alternate
cause such as ageing.
Increasing prevalence of hypogonadism in adult men worldwide is
expected to drive growth of the testosterone replacement therapy
market. According to the European Association of Urology: 2016
report, in middle-aged men, the incidence of hypogonadism varies from
2.1% to 12.8%. The incidence of low testosterone and symptoms of
hypogonadism in men aged 40-79 varies form 2.1% to 5.7%, in Europe.
Hypogonadism is more prevalent in older men, in men with obesity,
those with co-morbidities, and in men with a poor health status.
Furthermore, according to the Therapeutics Advances of Urology
Journal: 2016, testosterone has become one of the most widely
prescribed medications in the U.S. in 2011. These increase resulted
in significant growth of testosterone replacement therapy, from US$
18 million in the 1980 to US$ 1.6 billion in 2011, resulting in
five-fold increase.
Testosterone Replacement Therapy Market – Regional Analysis
Geographically, global testosterone replacement therapy market is
segmented into North America, Latin America, Europe, Middle East,
Asia Pacific, and Africa. North America holds major share in the
testosterone replacement therapy market, owing to increasing number
of people suffering from hypogonadism, combined with rising adoption
of testosterone products in the U.S. market. According to the data
published in European Association of Urology Journal: 2017,
testosterone prescription trends in the U.S. demonstrated an increase
between 1.8-and 4-fold over the last two decades (1997 - 2017).
Moreover, from 2000 to 2011, there was a 4.3-fold increase in
testosterone testing compared to a 3.7-fold increase in
prescriptions.
Testosterone Replacement Therapy Market – Competitor
Some of the key players operating in the testosterone replacement
therapy market include AbbVie, Inc., Bayer AG, Endo Pharmaceuticals,
Inc., Eli Lilly and Company, Kyowa Kirin International plc, Pfizer,
Inc., Acerus Pharmaceuticals Corporation, and Perrigo Company plc.
Testosterone Replacement Therapy Market – Taxonomy
By Active Ingredient Type:
-
Testosterone
-
Methyl Testosterone
-
Testosterone Undecanoate
-
Testosterone Enanthate
-
Testosterone Cypionate
By Route of Administration:
-
Injectables
-
Parenteral
By Region:
-
North America
-
Latin America
-
Europe
-
Asia Pacific
-
Middle East
-
Africa
For
More Information, Browse Here:
https://www.coherentmarketinsights.com/ongoing-insight/testosterone-replacement-therapy-market-2024
Also,
Coherent Market Insights has a proprietary database of pipeline
biologics and biosimilars, called PHASE-XS. This database provides
analytical data in addition to the clinical information of ongoing
trials for biologics and biosimilars. An amalgamation of more than 30
parameters, PHASE-XS helps biotechnology and pharmaceutical companies
to analyze the market trend, competition, and market potential. For
more information or to access this database,
kindly click on the below link or contact at
sales@coherentmarketinsights.com
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and
consulting firm offering action-ready syndicated research reports,
custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
No comments:
Post a Comment